Graduate Program in Nutrition, Health Sciences Center, Federal University of Santa Catarina, Florianópolis, SC, 88040-900, Brazil.
Biochemistry Department, Biological Science Center, Federal University of Santa Catarina, Florianópolis, SC, 88040-900, Brazil.
Naunyn Schmiedebergs Arch Pharmacol. 2020 Jan;393(1):111-120. doi: 10.1007/s00210-019-01714-2. Epub 2019 Aug 28.
Major depressive disorder (or depression) is one of the most frequent psychiatric illnesses in the population, with chronic stress being one of the main etiological factors. Studies have shown that cholecalciferol supplementation can lead to attenuation of the depressive state; however, the biochemical mechanisms involved in the relationship between cholecalciferol and depression are not very well known. The objective of this study was to investigate the effects of the administration of cholecalciferol on behavioral parameters (tail suspension test (TST), open field test (OFT), splash test (ST)) and redox state (dichlorofluorescein (DCF)) in adult female Swiss mice subjected to a model of depression induced by chronic corticosterone treatment. Corticosterone (20 mg/kg, p.o.) was administered once a day for 21 days. For investigation of the antidepressant-like effect, cholecalciferol (100 IU/kg) or fluoxetine (10 mg/kg, positive control) was administered p.o. within the last 7 days of corticosterone administration. After the treatments, the behavioral tests and biochemical analyses in the hippocampus and prefrontal cortex of the rodent samples were performed. Animals submitted to repeated corticosterone administration showed a depressive-like behavior, evidenced by a significant increase in the immobility time in the TST, which was significantly reduced by the administration of cholecalciferol or fluoxetine. In addition, the groups treated with cholecalciferol and fluoxetine showed a significant decrease in the production of reactive oxygen species (ROS) in the hippocampus. These results show that cholecalciferol, similar to fluoxetine, has a potential antidepressant-like effect, which may be related to the lower ROS production.
重度抑郁症（或抑郁）是人群中最常见的精神疾病之一，慢性应激是主要的发病因素之一。研究表明，胆钙化醇补充剂可以减轻抑郁状态；然而，胆钙化醇与抑郁症之间关系的生化机制尚不清楚。本研究旨在探讨胆钙化醇对慢性皮质酮处理诱导的抑郁模型成年雌性瑞士小鼠行为参数（悬尾试验（TST）、旷场试验（OFT）、溅水试验（ST））和氧化还原状态（二氯荧光素（DCF））的影响。皮质酮（20mg/kg，口服）每天给药一次，共 21 天。为了研究抗抑郁样作用，胆钙化醇（100IU/kg）或氟西汀（10mg/kg，阳性对照）在皮质酮给药的最后 7 天内口服给药。治疗后，对啮齿动物样本的海马体和前额叶皮层进行行为测试和生化分析。反复给予皮质酮的动物表现出类似抑郁的行为，悬尾试验（TST）中不动时间显著增加，这一现象可被胆钙化醇或氟西汀给药显著减轻。此外，给予胆钙化醇和氟西汀的组在海马体中产生的活性氧（ROS）显著减少。这些结果表明，胆钙化醇与氟西汀相似，具有潜在的抗抑郁样作用，这可能与较低的 ROS 产生有关。
